Merck & Company Inc (MRK)vsSight Sciences Inc (SGHT)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SGHT
Sight Sciences Inc
$4.09
+3.02%
HEALTHCARE · Cap: $237.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 83934% more annual revenue ($65.01B vs $77.36M). MRK leads profitability with a 28.1% profit margin vs -49.7%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SGHT
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+36.9%
Fair Value
$8.76
Current Price
$4.09
$4.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -50.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SGHT
SGHT has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SGHT
The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.49 — expect wider price swings.
SGHT is growing revenue faster at 6.9% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 25/100), backed by strong 28.1% margins. SGHT offers better value entry with a 36.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is a leading medical technology innovator dedicated to revolutionizing the management of eye diseases, particularly glaucoma, through both surgical and non-surgical solutions. The company boasts a diverse array of advanced products and a solid intellectual property portfolio, strategically positioning it to leverage the growing demand for minimally invasive ophthalmic therapies. As Sight Sciences continues to enhance its distribution capabilities and push the boundaries of eye care technology, it represents a compelling investment opportunity for institutional investors seeking exposure in the evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?